Results(4699)
EMR200098_008: Prospective and retrospective, single-cohort, multicenter observational long-term study in short children born small for gestational age (SGA) after treatment with Saizen® or with other recombinant human growth hormone (r-hGH) products (SALTO)
France
Germany
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS16520
First published:
08/05/2026
Study
Discontinued
id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000012
First published:
08/05/2026
Study
Ongoing
id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000035
First published:
08/05/2026
Study
Ongoing
A regulatory non-interventional study to monitor the safety and efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean patients with Chronic Kidney Disease (CKD)
Korea, Republic of
EU PAS number:
EUPAS107293
First published:
08/05/2026
Study
Finalised
An Observational Study of Ocrelizumab Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (VERISMO Study)
Germany
United States
EU PAS number:
EUPAS30752
First published:
08/05/2026
Study
Ongoing
Effectiveness and Safety of Avacopan as Add-on to Standard of Care (SOC) Versus SOC Alone in ANCA-associated Vasculitis (LIBRA) (20240051)
United States
EU PAS number:
EUPAS1000000985
First published:
08/05/2026
Study
Ongoing
Aarhus University & Aarhus University Hospital DEPARTMENT OF CLINICAL EPIDEMIOLOGY
Denmark
First published:
08/05/2026
Institution
Educational Institution
Safety and effectiveness of RZV in adults ≥18 years of age with Systemic lupus erythematosus (SLE) or Multiple sclerosis (MS) (EPI-ZOSTER-041 VS US DB 215104)
United States
EU PAS number:
EUPAS107073
First published:
08/05/2026
Study
Ongoing
Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States
United States
EU PAS number:
EUPAS108135
First published:
06/05/2026
Study
Finalised
Global Registry For Novel Therapies In Bone & Endocrine Conditions (GloBE-Reg)
Disease registry
Argentina
Armenia
Australia
Belgium
Brazil
Bulgaria
China
Czechia
France
Georgia
Germany
Greece
Hong Kong
Italy
Korea, Republic of
Malaysia
Poland
Portugal
Saudi Arabia
Slovenia
Sri Lanka
Sweden
United Kingdom
United States
First published:
06/05/2026
Data source
Human
Record completeness: 93%
The UK-Irish Atopic Eczema Systemic Therapy Register
Disease registry
Ireland
United Kingdom
First published:
06/05/2026
Data source
Human
Record completeness: 78%
DARWIN EU® - Enabling pregnancy and mother-child research in DARWIN EU® Data Network - PeriNet
Croatia
Denmark
Finland
France
Germany
Hungary
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000812
First published:
06/05/2026
Study
Ongoing
Croatia National Public Health Information System (Nacionalni javnozdravstveni informacijski sustav)
Administrative healthcare records (e.g., claims)
Birth registry
Cancer registry
Death registry
Diagnostic tests or procedures reimbursement
Disease registry
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Induced terminations registry
Other
Primary care medical records
Registration with healthcare system
Specialist ambulatory care records
Vaccination registry
Croatia
First published:
06/05/2026
Data source
Human
Record completeness: 97%
Norwegian Linked Health registry at University of Oslo, Pregnancy cohort
Birth registry
Hospital inpatient records
Hospital outpatient visit records
Pharmacy dispensing records
Primary care medical records
Norway
First published:
06/05/2026
Data source
Human
Record completeness: 93%
UK Biobank
Biobank
Death registry
Other
United Kingdom
First published:
05/05/2026
Data source
Human
Record completeness: 97%
A study to assess utilisation and safety of Glycopyrronium Bromide 1mg/5ml Oral Solution as licensed for symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders in the UK
United Kingdom
EU PAS number:
EUPAS103644
First published:
05/05/2026
Study
Finalised
Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab
United States
EU PAS number:
EUPAS1000000853
First published:
05/05/2026
Study
Planned
Clinical Practice Research Datalink
Birth registry
Hospital discharge records
Other
Primary care medical records
United Kingdom
First published:
05/05/2026
Data source
Human
Record completeness: 94%
Observational study to assess the characteristics and outcomes of patients with refractory/relapsed diffuse large B cell lymphoma who received R-GemOx as second line or above treatment (MK-2140-012)
China
EU PAS number:
EUPAS1000000973
First published:
04/05/2026
Study
Planned
Lane Clark and Peacock (LCP) LLP
France
Ireland
United Kingdom
First published:
04/05/2026
Institution
Non-Pharmaceutical company
ENCePP partner
A Phase 4 Observational, Real-World Study of 20-valent Pneumococcal Conjugate Vaccine Effectiveness Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged 65 years and above
Czechia
Israel
Spain
EU PAS number:
EUPAS1000000007
First published:
04/05/2026
Study
Ongoing
id.DRIVE (former COVIDRIVE)
Austria
Belgium
Canada
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain
United Kingdom
First published:
04/05/2026
Network
ENCePP partner
DARWIN EU - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe – supporting international preparedness
Denmark
Finland
Germany
Netherlands
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000969
First published:
04/05/2026
Study
Ongoing
Post-marketing Surveillance of Ofev Capsules in Chronic (PMS for PF-ILD)
Japan
EU PAS number:
EUPAS36605
First published:
04/05/2026
Study
Finalised
Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2025/2026 trivalent seasonal influenza vaccine in children, adolescents, adults and elderly subjects (3Fluart-H-36)
Hungary
EU PAS number:
EUPAS1000000581
First published:
04/05/2026
Study
Finalised
Retrospective online survey to investigate user experiences with herbal medicines (phytopharmaceuticals)/PhytoVIS
Germany
EU PAS number:
EUPAS1000000991
First published:
04/05/2026
Study
Planned
Risk of 4 obesity-related cancers after GLP-1 receptor agonist use
United States
EU PAS number:
EUPAS1000000990
First published:
30/04/2026
Study
Planned
A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment
United States
EU PAS number:
EUPAS1000000766
First published:
30/04/2026
Study
Cancelled
Sylvia Lawry Centre for Multiple Sclerosis Research, The Human Motion Institute
Germany
First published:
29/04/2026
Institution
Not-for-profit
ENCePP partner
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Patients and/or Caregivers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240214)
United States
EU PAS number:
EUPAS1000000368
First published:
29/04/2026
Study
Ongoing
An Active Surveillance, Post-Authorization Study to Assess Tofacitinib Utilization Patterns and to Characterize the Safety of Tofacitinib Use in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from a US Administrative Healthcare Claims Database
United States
EU PAS number:
EUPAS36041
First published:
29/04/2026
Study
Ongoing
COHORT STUDY ON THE SAFETY OF BIMEKIZUMAB IN PATIENTS WITH PLAQUE PSORIASIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR HIDRADENITIS SUPPURATIVA: A NON-INTERVENTIONAL POST AUTHORIZATION STUDY
France
United States
EU PAS number:
EUPAS1000000003
First published:
29/04/2026
Study
Ongoing
CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)
Australia
France
Italy
Japan
Portugal
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000616
First published:
29/04/2026
Study
Ongoing
Team Gesundheit GKV Claims data
Administrative healthcare records (e.g., claims)
Germany
First published:
29/04/2026
Data source
Human
Record completeness: 83%
Semmelweis University Clinical Data
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Hungary
First published:
29/04/2026
Data source
Human
Record completeness: 91%
TaUH patient cohort (FinOMOP)
Hospital inpatient records
Hospital outpatient visit records
Finland
First published:
29/04/2026
Data source
Human
Record completeness: 97%
BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)
Hospital discharge records
Pharmacy dispensing records
Primary care medical records
Spain
First published:
29/04/2026
Data source
Human
Record completeness: 97%
Comparing Weight Gain on F/TAF and Placebo Using DISCOVER and iPrEx Study Data
Austria
Brazil
Canada
Denmark
Ecuador
France
Germany
Ireland
Italy
Netherlands
Peru
South Africa
Spain
Thailand
United Kingdom
United States
EU PAS number:
EUPAS1000000509
First published:
29/04/2026
Study
Finalised
European real-Life use of Eludril eXtra among 4 countries (ELEX4)
Bulgaria
Greece
Poland
Portugal
EU PAS number:
EUPAS1000000986
First published:
23/04/2026
Study
Finalised
Compare data sources
Compare data sources